Company profile

Volta Medical

Cardiology & Cardiovascular Health

Company profile

About Volta Medical

Volta Medical is a medical device company specializing in artificial intelligence solutions for cardiac electrophysiology, with a particular focus on complex atrial fibrillation (AF) and atrial tachycardia (AT). The company's mission is to aid in the assessment of complex arrhythmia pathologies through data-inspired AI technology. Volta has developed the VoltaPlex data collection and enrichment ecosystem for curated electrophysiology lab data, which feeds into a physician-validated machine learning methodology to support EP solutions. This framework has resulted in Volta's flagship product, Volta AF-Xplorer™ II, a Companion AI technology designed for real-time assessment of complex AF and AT. The system assists operators in the real-time manual or automatic annotation of 3D anatomical and electrical maps of human atria, identifying areas exhibiting spatiotemporal dispersion during atrial fibrillation or atrial tachycardia. Volta's technology addresses a critical clinical need: determining the right ablation approach for persistent AF, where clinical success rates in landmark studies are only approximately 50%. The company's AI can match the expertise of multi-year-trained electrophysiologists to analyze intracardiac atrial electrograms in real time and identify areas of interest potentially involved in the arrhythmia mechanism. Volta serves electrophysiologists and cardiac care providers treating complex substrate patients, including those with persistent AF, redo patients with pulmonary vein isolation, women with AF, and heart failure patients. The company has established one of the most ambitious clinical programs focused on the underserved complex AF patient population, including the landmark TAILORED-AF randomized controlled trial published in Nature Medicine.

Company description Volta Medical official website

Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Volta Medical?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • AF in women
  • AF with heart failure
  • Atrial Fibrillation (AF)
  • Atrial Tachycardia (AT)
  • Complex substrate AF
  • Persistent AF
  • Redo AF with pulmonary vein isolation

Who it serves

  • Cardiac catheterization labs
  • Electrophysiologists
  • Hospital EP departments
  • Interventional cardiology centers

Deployment & integration

Embedded · Other deployment with recorded integration context.

Geographic context

MarketsEuropean Union · France · Germany · United States
Company sourceOfficial website

Company milestones

Platform expansion

TAILORED-AF randomized controlled trial published in Nature Medicine (2025), RESTART Trial completed (2026), FDA clearance obtained, CE mark obtained, global headcount expected to reach nearly 100 team members by end of 2023

Partnerships

Recorded partners

No partners are currently listed.

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

Volta AF-Xplorer™ II

AI Companion Technology for assessment of complex AF and AT

Software · EmbeddedCompany source

VoltaPlex

Data Collection & Enrichment Process for EP lab data

Platform · OtherCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

Evidence position

Publications, clinical validation, and regulatory records connected to this Company appear here.

Research

Publications & preprints

Reablation of atrial fibrillation targeting electrogram dispersion in patients with isolated veins: The RESTART trial.

Heart rhythm · May 1, 2026

Targetable atrial tachycardias after artificial intelligence-guided ablation of persistent atrial fibrillation.

Heart rhythm · Mar 1, 2026

Artificial intelligence-guided personalized ablation improves freedom from atrial arrhythmia in heart failure: A sub-analysis of the TAILORED-AF trial.

Heart rhythm O2 · Feb 1, 2026

The use of a contact force-sensing very-high-power short-duration radiofrequency catheter leads to significant efficiency improvement for dispersion-based ablation of persistent atrial fibrillation.

Heart rhythm O2 · Nov 1, 2025

Women with persistent atrial fibrillation need more than pulmonary vein isolation: personalised extra-pulmonary vein ablation strategy vs. pulmonary vein isolation alone in the TAILORED-AF trial.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · Oct 31, 2025

Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial.

Nature medicine · Apr 1, 2025

Clinical validation

Clinical-trial records

No linked records are currently available.

Regulatory

Regulatory records

Volta AF-Xplorer II

K251518 · 510k · Sep 12, 2025

Volta AF-Xplorer

K243812 · 510k · May 9, 2025

Volta AF-Xplorer

K232616 · 510k · Sep 27, 2023

VX1+

K223516 · 510k · Jan 21, 2023

VX1

K201298 · 510k · Sep 16, 2020

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

Clinical success rates

Addresses persistent AF where landmark studies show only ~50% success

Arrhythmia-free survival

Significantly increased 12-month arrhythmia-free survival in women with persistent AF after one procedure

Freedom from AF/AT

High freedom from arrhythmia in redo patients with recurrent AF despite durable PVI

Quality of life improvement

Improved quality of life in redo patient population

NYHA class improvement

Greatest benefit in heart failure patients with NYHA class III symptoms

RESTART Trial (Multicenter)

AI-guided dispersion ablation for redo patients with recurrent AF despite durable pulmonary vein isolation

High freedom from arrhythmia, improved quality of life, and favorable safety profile in challenging redo population

TAILORED-AF Trial (Multicenter)

AI-guided tailored ablation for persistent atrial fibrillation patients compared to conventional PVI treatment

Significantly increased 12-month arrhythmia-free survival after one procedure; greater benefit in patients with longer AF duration and advanced atrial remodeling

Ev-AIFib Study

Artificial intelligence software standardization of electrogram-based ablation outcome for persistent atrial fibrillation

Robust validation of AI-based solution achieving standardized outcomes

TAILORED-AF Heart Failure Sub-Analysis

Personalized AI-guided ablation for heart failure patients with AF across all NYHA classes

Improved freedom from AF/AT compared with PVI across all NYHA classes; greatest benefit in NYHA class III patients with higher FFAF/AT after one or two procedures

TAILORED-AF Women Sub-Analysis

AI-guided tailored ablation for women with persistent AF who typically have more extensive atrial substrate and higher recurrence rates

Significantly increased 12-month arrhythmia-free survival after one procedure; potential reduction in sex-based disparities in outcomes

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

Julien Seitz

Co-Founder

Clément Bars

Co-Founder

Jérôme Kalifa

Co-Founder

Bill Hoffman

Executive Chairman of the Board of Directors

LinkedIn

06 · Company updates

Updates from Volta Medical

Recent articles published on Volta Medical's official website.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Cardiology & Cardiovascular Health

Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon